Can I Take Saw Palmetto with Leqvio (Inclisiran)?

How Inclisiran Works and Why That Matters for Interactions

Inclisiran is a synthetic small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, reducing LDL-cholesterol synthesis at the source. In the ORION-10 trial (N=1,561), inclisiran 284 mg produced a 52.3% placebo-adjusted reduction in LDL-C at Day 510, sustained across the dosing interval [1]. Because the drug reaches the liver via GalNAc ligand-mediated endosomal uptake rather than intestinal absorption followed by hepatic CYP450 metabolism, the usual interaction pathways that govern statin or fibrate co-administration simply do not apply in the same way [2].

Elimination Pathway: Why CYP450 Status Is Largely Irrelevant

After subcutaneous injection, inclisiran distributes rapidly to the liver. Plasma half-life is approximately 9 hours, but the pharmacodynamic effect lasts roughly 6 months because the drug remains active inside hepatocytes as the RISC (RNA-induced silencing complex) continues to degrade PCSK9 mRNA [2]. Renal excretion handles most systemic clearance. The FDA label for inclisiran confirms no clinically significant CYP450-mediated interactions have been identified [3].

This profile stands in contrast to many oral lipid-lowering agents. Atorvastatin, for example, is a CYP3A4 substrate and can have its plasma concentrations raised by strong inhibitors. Inclisiran does not share that vulnerability.

What the ORION Trial Program Tells Us About Supplement Co-Administration

The ORION-9, ORION-10, and ORION-11 trials enrolled patients with heterozygous familial hypercholesterolemia and established ASCVD. Supplement use was not a primary exclusion criterion, but the trials were not designed to detect herb-drug interactions. The FDA prescribing information for inclisiran (approved December 2021) lists no named herbal interactions [3].

What Saw Palmetto Does Pharmacologically

Saw palmetto (Serenoa repens) is a fat-soluble extract used most commonly for benign prostatic hyperplasia symptoms. Its proposed mechanisms include 5-alpha-reductase (5-AR) inhibition, weak androgen receptor antagonism, and inhibition of arachidonic acid metabolism. A Cochrane systematic review of 32 randomized trials found saw palmetto produced only marginal improvements over placebo for urinary symptom scores [4]. Mechanistic data from that same body of literature describes the antiplatelet and anti-inflammatory pathways that raise the interaction question for cardiac patients.

5-Alpha-Reductase Inhibition: Relevant to Inclisiran?

Saw palmetto inhibits both isoforms of 5-AR, reducing conversion of testosterone to dihydrotestosterone. This action has no direct pharmacological overlap with inclisiran's PCSK9-silencing mechanism. No shared enzyme, receptor, or signaling pathway connects the two. From a pharmacokinetic standpoint, 5-AR inhibition by saw palmetto does not alter hepatic siRNA processing [5].

Antiplatelet Activity: The Real Consideration

Saw palmetto inhibits arachidonic acid-derived thromboxane synthesis and may reduce platelet aggregation at standard doses of 160 to 320 mg daily. A review published in Phytomedicine documented antiplatelet effects comparable to low-dose aspirin in in vitro platelet aggregation assays [6]. Inclisiran itself carries no antiplatelet or anticoagulant pharmacology, it does not affect coagulation factors. The concern arises only when a patient takes saw palmetto alongside an anticoagulant (warfarin, apixaban, rivaroxaban) that is co-prescribed with inclisiran therapy, creating an additive bleeding pathway through a third agent rather than a direct two-drug effect.

Hepatic Enzyme Interaction Profile

Saw palmetto shows weak inhibitory activity against CYP2C9 and CYP3A4 in vitro, though in vivo studies have not confirmed clinically significant inhibition at doses used therapeutically [7]. Because inclisiran does not rely on these enzymes for metabolism or activation, even if saw palmetto produced modest CYP inhibition in a given patient, inclisiran plasma concentrations would be unlikely to change meaningfully.

Pharmacokinetic vs. Pharmacodynamic Interaction: A Clear Distinction

Clinically, drug-supplement interactions fall into two categories. Pharmacokinetic interactions change how much drug reaches its target (absorption, distribution, metabolism, excretion). Pharmacodynamic interactions change what the drug does at the target, either amplifying or opposing its effect.

Pharmacokinetic verdict: Low risk. Inclisiran bypasses oral first-pass CYP450 metabolism entirely. Saw palmetto cannot meaningfully alter the plasma concentration or hepatocyte uptake of inclisiran through the mechanisms currently known [2, 3].

Pharmacodynamic verdict: No direct overlap. Inclisiran reduces LDL-C by silencing PCSK9. Saw palmetto modulates androgen metabolism and prostaglandin synthesis. These pathways do not converge on a shared clinical endpoint that would amplify or blunt either agent's primary effect.

Indirect pharmacodynamic risk: Mild. If anticoagulants are part of the patient's regimen (common in ASCVD), saw palmetto's antiplatelet properties may add to bleeding risk. This is the one scenario that requires a conversation with the prescribing clinician [6].

Evidence Quality and What Is Still Unknown

The absence of a confirmed interaction is not the same as confirmed safety. No randomized controlled trial, pharmacokinetic study, or case series has specifically examined inclisiran plus saw palmetto co-administration. The evidence base is mechanistic inference drawn from:

• Inclisiran's known elimination pathway (FDA label, ORION program pharmacokinetic data) [2, 3]
• Saw palmetto's in vitro and in vivo pharmacology (Cochrane review, Phytomedicine data) [4, 6]
• General principles of siRNA pharmacology published in peer-reviewed journals [5]

The American Heart Association's 2023 scientific statement on dietary supplements and cardiovascular disease notes that herbal products with antiplatelet activity require disclosure to the treating physician in any patient on anticoagulation or antiplatelet therapy [8]. That guidance applies here when inclisiran is prescribed alongside anticoagulants.

Why Absence of Data Does Not Equal "Safe to Combine Without Telling Your Doctor"

Patients with familial hypercholesterolemia or established ASCVD often carry multiple cardiovascular risk factors and take five or more prescription medications. Saw palmetto is frequently not listed on medication reconciliation forms because patients view it as a food supplement. A 2017 survey published in JAMA Internal Medicine found that 69% of adults who used dietary supplements did not disclose their use to a physician [9]. That disclosure gap is directly relevant to patients on Leqvio, where anticoagulants or antiplatelet agents are often co-prescribed.

Dose and Duration Considerations

Standard saw palmetto dosing is 160 mg twice daily of a lipophilic extract standardized to 85 to 95% fatty acids and sterols. Higher doses (up to 960 mg daily in some BPH protocols) produce more pronounced antiplatelet effects in vitro [6]. Patients taking above-standard doses alongside anticoagulants represent the highest-risk subgroup for additive bleeding, even though the inclisiran-saw palmetto component of that equation remains low risk in isolation.

Monitoring and What to Do If You Are Already Taking Both

If you are currently taking saw palmetto and starting inclisiran, three steps apply.

First, disclose the supplement to the clinician managing your lipid therapy. Medication reconciliation at each Leqvio injection visit (every 6 months) is standard practice and should include all supplements. The American College of Cardiology's lipid management pathway recommends full medication and supplement review at every PCSK9 inhibitor or siRNA therapy follow-up [10].

Second, if anticoagulants such as warfarin are part of your regimen, request an INR check 4 to 6 weeks after adding or changing saw palmetto dose. Saw palmetto's interaction with warfarin has been documented in case reports, with one published in the Annals of Pharmacotherapy describing an elevated INR in a patient on stable warfarin who began saw palmetto 320 mg daily [11].

Third, watch for signs of increased bleeding: prolonged bruising, heavier menstrual flow, prolonged bleeding from minor cuts, or blood in urine or stool. These are not expected from inclisiran alone but could emerge if saw palmetto potentiates anticoagulant effects through a third-agent interaction.

Laboratory Monitoring Specific to Inclisiran Therapy

The ORION trials used LDL-C at Day 510 as the primary efficacy endpoint. Routine monitoring for patients on inclisiran includes fasting lipid panel at the 3-month injection visit and then annually, along with liver function tests at baseline per institutional protocol [1, 3]. Saw palmetto has no known hepatotoxic interactions with inclisiran, but baseline ALT/AST values are worth documenting before combining any supplement with a hepatocyte-targeted therapy.

When to Stop Saw Palmetto

A prescribing clinician may recommend pausing saw palmetto 7 to 10 days before any planned surgical procedure, given its antiplatelet activity. This recommendation mirrors guidance for fish oil and vitamin E in the perioperative setting. Outside of surgery or the addition of a new anticoagulant, routine discontinuation of saw palmetto is not required based on current evidence for patients on inclisiran alone.

What Clinicians and Guidelines Say

The Endocrine Society's 2017 clinical practice guideline on dyslipidemia does not specifically address herbal supplement combinations with newer RNA-based therapies, reflecting the timeline of inclisiran's approval [12]. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol, updated with a focused update in 2022, states: "Clinicians should ask patients about use of all drugs, vitamins, and dietary supplements, as these may affect lipid levels or interact with lipid-lowering therapies" [10].

The Natural Medicines database (a professional reference for clinicians) rates the inclisiran-saw palmetto combination as having insufficient evidence for a definitive interaction rating, which reflects the absence of direct study data rather than confirmed safety [13].

"Patients often assume that because something is natural, it is automatically safe with their prescription medications. With cardiac therapies, that assumption can be dangerous, particularly when anticoagulation is involved," according to a clinical pharmacist commentary published in the American Journal of Health-System Pharmacy on supplement disclosure in cardiology practices [14].

Practical Guidance for Patients

Saw palmetto does not block inclisiran's mechanism of action. It does not appear to alter inclisiran pharmacokinetics based on what is currently understood about both agents. The indirect risk through antiplatelet activity is real but manageable with disclosure and appropriate monitoring.

Tell your prescribing clinician before combining the two. That single step converts an unknown variable into a monitored one.